ATH alterity therapeutics limited

Ann: Alterity Presents Data Describing Neuroprotection of ATH434, page-4

  1. 3,287 Posts.
    lightbulb Created with Sketch. 300
    Absoluetly, confirmed significant reduction in NfL , confirmed reduction in iron levels, confirmed brain mass loss stabilisation, confirmed mitochodrial protection...incredibly hard to see we wont smash the 201 study and get FDA approval, plus extension into other studies.

    I will continue to make purchases for this stock, 7wks unyil the 201 study is complete.

    Does anyone know if those in the 202 study are still taking ATH434 post their 12mnth completion ?
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.1¢
Change
0.000(0.00%)
Mkt cap ! $100.4M
Open High Low Value Volume
1.1¢ 1.1¢ 1.1¢ $88.06K 8.054M

Buyers (Bids)

No. Vol. Price($)
29 11330464 1.0¢
 

Sellers (Offers)

Price($) Vol. No.
1.1¢ 1574126 5
View Market Depth
Last trade - 16.10pm 17/06/2025 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.